Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-T Targeting CEA in Advanced Malignant Solid Tumors
NCT05538195Phase 2Completed
- Sponsor
- Chongqing Precision Biotech
- Start
- Jun 2022
- Primary completion
- Dec 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label trial of C-13-60 in gastric cancer (GC), colon cancer, rectal cancer and 2 more (2 arms), sponsored by Chongqing Precision Biotech. Primary endpoints: Safety and Tolerability at 1 month and Recommended dose and infusion regimen at 28 days. Started Jun 2022; status: completed.
02
Drugs
C-13-60
03
Conditions
gastric cancer (GC)colon cancerrectal canceresophageal cancerpancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05538195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05538195.